Asciminib for Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase after two or more tyrosine kinase inhibitors
Agency for Care Effectiveness (ACE)
Record ID 32018014277
English
Details
Project Status:
Completed
Year Published:
2025
URL for published report:
https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidances/drug-guidance/asciminib-for-philadelphia-chromosome-positive-chronic-myeloid-leukaemia-in-chronic-phase-after-two-or-more-tyrosine-kinase-inhibitors
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Singapore
MeSH Terms
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myeloid, Chronic-Phase
- Tyrosine Kinase Inhibitors
- Protein Kinase Inhibitors
- Antineoplastic Agents
Contact
Organisation Name:
Agency for Care Effectiveness (ACE)
Contact Address:
Ministry of Health, College of Medicine Building, 16 College Road, Singapore 169854
Contact Name:
ACE_HTA@moh.gov.sg
Contact Email:
ACE_HTA@moh.gov.sg
Copyright:
Agency for Care Effectiveness (ACE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.